Skip to content
Starlix(nateglinide)
Starlix, Trazec (nateglinide) is a small molecule pharmaceutical. Nateglinide was first approved as Starlix on 2000-12-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Nateglinide
Tradename
Company
Number
Date
Products
STARLIXNovartisN-021204 DISCN2000-12-22
2 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
nateglinideANDA2023-02-28
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
type 2 diabetes mellitusEFO_0001360D003924E11
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10B: Blood glucose lowering drugs, excl. insulins
— A10BX: Other blood glucose lowering drugs, excl. insulins in atc
— A10BX03: Nateglinide
HCPCS
No data
Clinical
Clinical Trials
16 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11—138—11
Insulin resistanceD007333EFO_0002614———2—2
Diabetes mellitusD003920EFO_0000400E08-E13———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3————3
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameNATEGLINIDE
INNnateglinide
Description
(2S)-2-[[oxo-(4-propan-2-ylcyclohexyl)methyl]amino]-3-phenylpropanoic acid is a phenylalanine derivative.
Classification
Small molecule
Drug classantidiabetic, sodium glucose co-transporter 2 (SGLT2) inhibitors, not phlorozin derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(C)[C@H]1CC[C@H](C(=O)N[C@H](Cc2ccccc2)C(=O)O)CC1
Identifiers
PDB—
CAS-ID105816-04-4
RxCUI274332
ChEMBL IDCHEMBL783
ChEBI ID31897
PubChem CID60026
DrugBankDB00731
UNII ID41X3PWK4O2 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,661 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
193,251 adverse events reported
View more details